P Barthélémy

Prospective gerandomiseerde phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal ce...

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year...